Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Teratogenicity

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Endometriosis and ovarian cancer risk.

Gynecologic oncology·2026

Same author

ESGO Consensus Statement on endometrial cancer prevention, risk reduction strategies, and management of women with Lynch syndrome.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Design, development and characterization of pregnant anthropomorphic phantoms for fetal dose measurements in proton therapy.

Physics in medicine and biology·2026

Same author

Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Response: Cancer in pregnancy: FIGO Best practice advice and narrative review.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026

Same author

The association between parity, age of first full term pregnancy and invasive lobular breast cancer: a case-only analysis.

Cancer treatment and research communications·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Chemotherapy during pregnancy.

Frédéric Amant¹, Sileny N Han, Mina M Gziri

¹Leuven Cancer Institute, Division of Gynaecological Oncology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. frederic.amant@uzleuven.be

Current Opinion in Oncology

|May 15, 2012

Summary

This summary is machine-generated.

Chemotherapy can be safely administered during pregnancy after 14 weeks gestation. While fetal outcomes are generally comparable, preterm birth may increase neurodevelopmental issues.

Related Experiment Videos

Last Updated: May 22, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

Area of Science:

Obstetrics and Gynecology
Oncology
Perinatal Medicine

Background:

Cancer complicating pregnancy is becoming more common due to delayed childbearing.
Multidisciplinary management is crucial for cancer staging and treatment during pregnancy.
Chemotherapy administration during pregnancy is a viable treatment option.

Purpose of the Study:

To review the current understanding and practice of administering chemotherapy during pregnancy.
To highlight safety considerations and outcomes for both mother and fetus.
To discuss the timing and potential benefits of antenatal chemotherapy.

Main Methods:

Review of recent data on chemotherapy administration from 14 weeks gestational age.
Analysis of placental transfer and maternal physiological changes affecting chemotherapy.
Evaluation of long-term outcomes in children exposed to antenatal chemotherapy.

Main Results:

Chemotherapy can be administered from 14 weeks gestation; placental barrier offers some fetal protection.
Maternal physiological changes may alter chemotherapy serum levels, with unknown pharmacodynamic impact.
Long-term outcomes for children are comparable, but preterm birth is linked to neurodevelopmental issues.

Conclusions:

Antenatal chemotherapy administration can potentially reduce the incidence of early delivery and prematurity.
Careful timing (avoiding late pregnancy) is recommended to optimize outcomes.
Further research is needed to fully understand pharmacodynamic impacts and long-term neurodevelopmental effects.